In 2017 the ALS TDI reported the first instance in which they were able to successfully and independently validate a previously reported positive therapeutic outcome from a pre-clinical study involving mutant SOD1 mice. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.